ストックスクリーナーアプリを入手
1.575
0.96%
0.015
前日終値:
$1.56
開ける：
$1.56
24時間の取引高:
66,946
Relative Volume:
0.24
時価総額：
$67.55M
収益：
$51.13M
当期純損益:
$-93.80M
株価収益率:
-0.7063
EPS:
-2.23
ネットキャッシュフロー:
$-129.10M
1週間 パフォーマンス:
+2.94%
1か月 パフォーマンス:
+5.00%
6か月 パフォーマンス:
+31.25%
1年 パフォーマンス:
-46.79%
1日の値動き範囲:
$1.56
$1.59
1週間の範囲:
$1.48
$1.59
52週間の値動き範囲:
$0.89
$4.0695
Repare Therapeutics Inc Stock (RPTX) Company Profile
名前
Repare Therapeutics Inc
セクター
電話
(857) 412-7018
住所
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.575 | 66.05M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.61 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.27 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.15 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.33 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.24 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-06-09 | アップグレード | Stifel | Hold → Buy |
| 2023-02-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 開始されました | CapitalOne | Overweight |
| 2022-04-12 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-17 | 再開されました | Goldman | Buy |
| 2021-09-23 | 開始されました | Stifel | Buy |
| 2021-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2021-06-28 | 開始されました | Guggenheim | Buy |
| 2021-03-01 | 開始されました | Berenberg | Buy |
| 2020-10-28 | 開始されました | Northland Capital | Outperform |
| 2020-07-14 | 開始されました | Cowen | Outperform |
| 2020-07-14 | 開始されました | Goldman | Neutral |
| 2020-07-14 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-14 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Repare Therapeutics Inc (RPTX) 最新ニュース
Repare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Candlestick Reversal Detected on Repare Therapeutics Inc.’s ChartScalable Portfolio Growth Suggestions Released - 선데이타임즈
Is Repare Therapeutics Inc. still worth holding after the dipFree Risk-Adjusted Picks With Exit Strategy - Newser
Using portfolio simulators with Repare Therapeutics Inc. includedSafe Investment Ideas with Growth Upside - Newser
Repare Therapeutics (NASDAQ:RPTX) Issues Quarterly Earnings Results - MarketBeat
Is Repare Therapeutics Inc. forming a reversal patternFree Market Surge Signal for Swing Traders - Newser
Backtesting results for Repare Therapeutics Inc. trading strategiesPattern Recognition Based Market Move Prediction - Newser
Is Repare Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSafe Momentum Strategy With Trend Analysis - Newser
Repare Therapeutics Q2 2025 Earnings: EPS Beats Estimates, Revenue Surpasses Expectations - AInvest
Repare Therapeutics Inc (RPTX) Q2 2025 Earnings: EPS of -$0.39 B - GuruFocus
Will Repare Therapeutics Inc. benefit from macro trendsDay Trading Plan with Entry Risk Management - Newser
Analyzing recovery setups for Repare Therapeutics Inc. investorsFree Smart Trend Trading with Weekly Signals - Newser
Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Repare Therapeutics Reports Q2 2025 Results and Strategic Moves - TipRanks
Repare Therapeutics Reports Q2 Earnings: Strategic Moves and Upcoming Data Releases - AInvest
Repare Therapeutics Announces Licensing Deal and Strategic Updates - The Globe and Mail
Repare 2025 Q2 Earnings Strong Improvement as Net Loss Narrows 51.8% - AInvest
Repare Therapeutics Cuts Losses And Snags New Licensing Deals - Finimize
Repare Therapeutics Narrows Losses And Seeks New Paths Forward - Finimize
Repare (RPTX) Q2 Loss Narrows 52% - AOL.com
Repare Therapeutics' Strategic Shift and Milestone-Driven Outlook - AInvest
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year - TipRanks
Repare Therapeutics Inc. SEC 10-Q Report - TradingView
Repare Therapeutics Q2 net loss narrows to $16.7 mln - MarketScreener
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | RPTX Stock News - GuruFocus
Repare Therapeutics reports Q2 2025 revenue $109.5 mln, cash & marketable securities. - AInvest
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - The Globe and Mail
Predicting Repare Therapeutics Inc. trend using moving averagesChart Scanner for Swing Trade Timing - Newser
Repare Therapeutics Provides Business Update and Reports Second - GuruFocus
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Daily Profit Focused Stock Screener - Newser
Can Repare Therapeutics Inc. hit a new high this monthFree Low Risk Swing Trade Opportunity List - Newser
Quantitative breakdown of Repare Therapeutics Inc. recent movePredicted Market Direction Based on Momentum - Newser
What makes Repare Therapeutics Inc. stock price move sharplyUnlock market-leading stock analysis - Jammu Links News
Should I hold or sell Repare Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
Repare Therapeutics Inc. Stock Analysis and ForecastAchieve rapid wealth accumulation with smart picks - Jammu Links News
How volatile is Repare Therapeutics Inc. stock compared to the marketMaximize portfolio value with smart investment plans - Jammu Links News
When is Repare Therapeutics Inc. stock expected to show significant growthAmplify your gains with low-risk picks - Jammu Links News
Does Repare Therapeutics Inc. stock perform well during market downturnsMaximize returns with data-driven strategies - Jammu Links News
Is Repare Therapeutics Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - Jammu Links News
How many analysts rate Repare Therapeutics Inc. as a “Buy”Capitalize on momentum stocks before they peak - Jammu Links News
Repare Therapeutics Inc (RPTX) 財務データ
収益
当期純利益
現金流量
EPS
0.79%
0.06%
大文字化:
|
ボリューム (24 時間):